Clincosm LogoSign in Get a demo

Squamous Cell Carcinoma

Showing 26 - 50 of 205
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sputum DNA Testing for Lung Cancer in China

Recruiting
  • Lung Cancer
  • +15 more
  • Diagnostic Test: Sputum DNA methylation analysis
  • chest CT or pathological examination
  • Guangzhou, Guangdong, China
    Nanfang Hospital of Southern Medccal University
Dec 29, 2022

Squamous Cell Carcinoma Trial in Tampa (Afatinib 40 MG)

Recruiting
  • Squamous Cell Carcinoma
  • Afatinib 40 MG
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Electronic Brachytherapy for the Treatment of NMSC

Completed
  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma
  • electronic brachytherapy
  • Tuscaloosa, Alabama
  • +4 more
Dec 9, 2022

Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma Trial in Indianapolis (sentinel lymph node

Recruiting
  • Squamous Cell Carcinoma
  • +2 more
  • sentinel lymph node biopsy (SLNB)
  • Indianapolis, Indiana
    Indiana University Melvin & Bren Simon Cancer Center
Nov 15, 2022

T1 Squamous Cell Carcinomas of the Lip

Active, not recruiting
  • Lip
  • +9 more
    • Nijmegen, Gelderland, Netherlands
    • +2 more
    Nov 2, 2022

    Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer Trial in Duarte, Louisville, New York (PF-07263689, Sasanlimab)

    Active, not recruiting
    • Renal Cell Cancer
    • +9 more
    • PF-07263689
    • Sasanlimab
    • Duarte, California
    • +5 more
    Nov 8, 2022

    Epidermolysis Bullosa Dystrophica, Squamous Cell Carcinoma Trial in Salzburg (Rigosertib Oral Capsules / Rigosertib Intravenous)

    Recruiting
    • Epidermolysis Bullosa Dystrophica
    • Squamous Cell Carcinoma
    • Rigosertib Oral Capsules / Rigosertib Intravenous
    • Salzburg, Austria
      EB House Austria/Dept. of Dermatology University Hospital
    Nov 3, 2022

    Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma Trial in United States (Cemiplimab, Radiotherapy)

    Recruiting
    • Cutaneous Squamous Cell Carcinoma
    • +6 more
    • Aurora, Colorado
    • +11 more
    Oct 12, 2022

    Progression of Invasive Squamous Cell Carcinoma

    Recruiting
    • Carcinoma, Squamous Cell
    • +10 more
    • DNA Extraction
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Sep 27, 2022

    Esophageal Cancer, Metastatic Cancer, Squamous Cell Carcinoma Trial in Taipei City (Cabozantinib 40 MG, Atezolizumab Injection)

    Recruiting
    • Esophageal Cancer
    • +2 more
    • Cabozantinib 40 MG
    • Atezolizumab Injection
    • Taipei City, Taiwan
      National Taiwan University Hospital
    Sep 15, 2022

    Squamous Cell Carcinoma, Oropharynx Cancer, Head Neck Cancer Trial in Houston (SAR444245, Cemiplimab)

    Not yet recruiting
    • Squamous Cell Carcinoma
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 7, 2022

    Esophageal Tumor, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer Trial in United States (DKN-01)

    Available
    • Esophageal Neoplasm
    • +9 more
    • Birmingham, Alabama
    • +3 more
    Aug 24, 2022

    DERM US and EU Validation Study

    Active, not recruiting
    • Malignant Skin Melanoma T0
    • +2 more
    • Deep Ensemble for the Recognition of Malignancy (DERM)
    • Redwood City, California
    • +15 more
    Aug 23, 2022

    Squamous Cell Carcinoma Trial in New York (Standard surveillance, Telemedicine surveillance (tele-surveillance), Questionnaires)

    Recruiting
    • Squamous Cell Carcinoma
    • Standard surveillance
    • +2 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    Aug 17, 2022

    Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses Trial in Houston (Pembrolizumab, Docetaxel, Cisplatin)

    Recruiting
    • Squamous Cell Carcinoma
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 10, 2022

    Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Jerusalem (Radiation: Diffusing Alpha Radiation Emitters

    Not yet recruiting
    • Squamous Cell Carcinoma
    • Head and Neck Squamous Cell Carcinoma
    • Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
    • Jerusalem, Israel
      Sharett institute, Hadassah University Hospital - Ein-Kerem
    Jul 4, 2022

    Breast Cancer, Head Neck Cancer, Squamous Cell Carcinoma Trial in Canada, United States (INT230-6, anti-PD-1 antibody,

    Active, not recruiting
    • Breast Cancer
    • +10 more
    • Los Angeles, California
    • +7 more
    Jun 21, 2022

    Squamous Cell Carcinoma Trial in Pittsburgh (Pembrolizumab Injection)

    Recruiting
    • Squamous Cell Carcinoma
    • Pembrolizumab Injection
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Jun 21, 2022

    Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Trial in Chicago (Carboplatin,

    Recruiting
    • Human Papilloma Virus
    • +4 more
    • Chicago, Illinois
      University Of Chicago Medicine Comprehensive Cancer Center
    Jun 3, 2022

    Melanoma (Skin), Nevus, Nevus, Spitz Trial in Moscow, Nizhny Novgorod (Mobile phone application "ProRodinki")

    Recruiting
    • Melanoma (Skin)
    • +9 more
    • Mobile phone application "ProRodinki"
    • Moscow, Russian Federation
    • +1 more
    May 29, 2022

    Long Term Outcomes of SCC Patients Previously Treated With Alpha

    Completed
    • Squamous Cell Carcinoma
    • DaRT Treated Patients
      • Petah tikva, Israel
      • +1 more
      May 30, 2022

      Circulating Tumor DNA Kinetics in Immuno-oncology

      Completed
      • Head and Neck Cancer
      • +4 more
        • Toronto, Ontario, Canada
          Princess Margaret Cancer Centre
        May 16, 2022

        Head Neck Cancer, Squamous Cell Carcinoma Trial in London (Avelumab, Cetuximab)

        Active, not recruiting
        • Head and Neck Cancer
        • Squamous Cell Carcinoma
        • London, United Kingdom
          University College Hospital
        May 17, 2022

        Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1, Tongue Cancer TNM Staging Primary Tumor (T) T2 Trial in Seoul,

        Recruiting
        • Tongue Cancer
        • +5 more
        • 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers
        • 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
        • Seoul, Korea, Republic of
        • +3 more
        May 3, 2022

        NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)

        Terminated
        • Carcinoma, Non-Small-Cell Lung
        • Squamous Cell Carcinoma
        • Wuhan, Hubei, China
          Zhongnan Hospital of Wuhan University
        Apr 26, 2022